Wei Xu, MD, PhD

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China (People's Republic)

N/A

Poster(s):

• 1008 - XPO1 inhibitor Selinexor induces heme oxygenase-1 mediated p53-dependent ferroptosis in chronic lymphocytic leukemia

• 1017 - NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia

• 1047 - Prognosis Analysis and Validation of Fatty Acid Metabolism-Related Signature in Chronic lymphocytic leukemia

• 1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

• 1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients

• 1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia

• 1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL

• 1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort

• 1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)